Fingolimod approved!

…and so just a follow up on my previoud posts…

Fingolimod (Gilenya) has finally been approved by the FDA. Gilenya (fingolimod) is a 0.5 mg (capsule) daily oral treatment for relapsing MS.

Novartis, stated that Gilenya is the first oral medication indicated for relapsing forms of multiple sclerosis (MS) in the United States – it reduces the frequency of MS flare-up, as well as helping slow down the build-up of some of the physical problems associated with MS.

Yeay! more oral drugs – we like! : )


Oral Laquinimod for MS!

I’d like to mention briefly Laquinimod here..

Laquinimod is an investigational, novel, once-daily oral immunomodulator. It was developed as a disease-modifying treatment for RRMS and is nearing end of trial phase. It is expected to be completed by Q3 next year!

Besides being tested for the treatment of RRMS, it is in development for Crohn’s disease and Lupus, and is being researched for other autoimmune diseases as well!

On September 21st, Medical News Today reported that, thus far, Laquinimod has demonstrated a sustained positive benefit-risk profile through the trials undertaken. Doctors are looking forward to confirming these in the final study phases next year.

We have one more oral drug for MS to look forward to!! : )